Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology

604 Background: Renal cell carcinoma (RCC) is the third most common urologic malignancy worldwide, with clear cell subtype being the most common. In this study, we sought to investigate RCC incidence and mortality trends by demographic and tumor characteristics using data from the surveillance, epidemiology and end results (SEER) database. Methods: We used SEER database to study RCC cases between 1973 and 2014. Incidence and mortality rates were calculated by sex, age, race, state, stage, size, and histological subtype of RCC. Annual percent change (APC) was calculated using joinpoint regression software. Results: A total of 96,058 RCC cases were identified, with 54,000 RCC deaths between 1973 and 2014. Overall incidence was 9.712 per 100,000 persons-years, being highest among males (13.698), blacks (11.886), and people older than 65 years (38.693). Incidence rates of localized cases (5.845) and tumors smaller than 7 cm (6.550) were higher than other tumor subgroups with distant disease incidence of 1.773 per 100,000 persons-years. Overall incidence rates increased by 2.709% (95% CI, 2.544-2.875, p < .001) per year over the study period, but rates became stable since 2007 with only an increase in the incidence of clear-cell subtype (2.538%; 95% CI, 1.300-3.791, p < .001). Overall RCC mortality rates have been declining since 2000, and distant disease mortality have been decreasing since 2008 with most profound decline in the period between 2012 and 2014 with APC of -22.635% (-37.419- -4.359, P = .019) Conclusions: Despite overall increase in rates over the last 40 years, recent years have shown stable incidence and decrease in mortality rates of RCC. The significant decline in mortality over the last 10 years since the approval of the first Vascular Endothelial Growth Factor ‘VEGF’ inhibitor highlights the impact of this class of medications along with other subsequent agents such as mTOR inhibitors and checkpoint inhibitors on the prognosis of renal cell carcinoma.

Download Full-text

1299 CONTEMPORARY INCIDENCE AND MORTALITY RATES OF RENAL CELL CARCINOMA IN THE UNITED STATES

The Journal of Urology ◽

10.1016/j.juro.2013.02.2653 ◽

2013 ◽

Vol 189 (4S) ◽

Cited By ~ 1

Author(s):

Maxine Sun ◽

Vincent QH Trinh ◽

Florian Roghmann ◽

Andreas Becker ◽

Hugo Lavigueur-Blouin ◽

...

Keyword(s):

United States ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

The United States ◽

Mortality Rates ◽

Incidence And Mortality

Download Full-text

Renal cell carcinoma in Ireland: rising mortality and survival

Journal of Clinical Urology ◽

10.1177/2051415818813784 ◽

2018 ◽

Vol 12 (3) ◽

pp. 217-222

Author(s):

Lee Chien Yap ◽

Frank Leonard ◽

Ivor Cullen ◽

Padraig Daly

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Developed Countries ◽

Mortality Rates ◽

Percentage Change ◽

Annual Percentage Change ◽

Level Of Evidence ◽

Female Population ◽

Incidence And Mortality

Objective: The objective of this study was to evaluate the rising trend in the incidence and mortality of renal cell carcinoma in Ireland. Methods: Data from the National Cancer Registry of Ireland on primary adenocarcinomas of the kidney from 2003 to 2013 were evaluated. Statistical analysis was performed on the data using IBM SPSS statistics V24 software package and Microsoft Excel Software. Results: There were 3801 cases of adenocarcinoma of the kidney with 29% of tumours (n=1103) being found incidentally. The age-adjusted incidence rate of renal cell carcinoma in 2003 was 4.66 per 100,000 women and 8.78 per 100,000 men. These figures have risen to 5.78 and 13.14 in 2013, respectively. There was an annual percentage change of +2.2% for women and +4.1% for men from the years 2003 to 2013. For both sexes the age-standardised all-cause mortality rate for renal adenocarcinoma increased from 1.07 per 100,000 in 2003 to 4.32 ± 0.06 per 100,000 in 2013, an annual percentage change of +15%. Age-adjusted mortality rates in the female population in Ireland increased from 0.78 to 2.66, an annual percentage change of +13.1% and from 1.41 to 6.04 in men, an annual percentage change of +15.8%. Conclusion: There is a paradox emerging in Ireland, with both rising survival rates for renal cell carcinoma and rising mortality rates. While the increased incidence of renal cell carcinoma in Ireland can be attributed somewhat to the increased use of various imaging modalities, it may also be attributed to the significant rise in modifiable risk factors as seen in other developed countries, namely hypertension, obesity, and smoking. Level of evidence: 2c

Download Full-text

Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis

European Urology ◽

10.1016/j.eururo.2010.10.029 ◽

2011 ◽

Vol 59 (1) ◽

pp. 135-141 ◽

Cited By ~ 189

Author(s):

Maxine Sun ◽

Rodolphe Thuret ◽

Firas Abdollah ◽

Giovanni Lughezzani ◽

Jan Schmitges ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

North America ◽

Cell Carcinoma ◽

Trend Analysis ◽

Renal Cell ◽

Survival Rates ◽

Adjusted Incidence

Download Full-text

NON-CANCER RELATED MORTALITY RATES IN EUROPEAN PATIENTS WITH T1A AND T1B RENAL CELL CARCINOMA

The Journal of Urology ◽

10.1016/s0022-5347(09)61329-x ◽

2009 ◽

Vol 181 (4S) ◽

pp. 469-469

Author(s):

Laurent Zini ◽

Jean-Jacques Patard ◽

Umberto Capitanio ◽

Maxime Crepel ◽

Alexandre de la Taille ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Mortality Rates ◽

Related Mortality

Download Full-text

A 17-Gene Signature Predicted Prognosis in Renal Cell Carcinoma

Disease Markers ◽

10.1155/2020/8352809 ◽

2020 ◽

Vol 2020 ◽

pp. 1-9

Author(s):

Fan Li ◽

Weifeng Hu ◽

Wei Zhang ◽

Guohao Li ◽

Yonglian Guo

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Malignant Tumors ◽

Prognostic Significance ◽

Gene Signature ◽

The Cancer Genome Atlas ◽

Prognostic Indicators ◽

Incidence And Mortality ◽

Tcga Dataset

Renal cell carcinoma (RCC), which was one of the most common malignant tumors in urinary system, had gradually increased incidence and mortality in recent years. Although significant advances had been made in molecular and biology research on the pathogenesis of RCC, effective treatments and prognostic indicators were still lacking. In order to predict the prognosis of RCC better, we identified 17 genes that were associated with the overall survival (OS) of RCC patients from The Cancer Genome Atlas (TCGA) dataset and a 17-gene signature was developed. Through SurvExpress, we analyzed the expression differences of the 17 genes and their correlation with the survival of RCC patients in five datasets (ZHAO, TCGA, KIPAN, KIRC, and KIRP), and then evaluated the survival prognostic significance of the 17-gene signature for RCC. Our results showed that the 17-gene signature had a predictive prognostic value not only in single pathologic RCC, but also in multiple pathologic types of RCC. In conclusion, the 17-gene signature model was related to the survival of RCC patients and could help predict the prognosis with significant clinical implications.

Download Full-text

Renal Cell Carcinoma – How Can We Predict its Outcomes in Clinical Practice?

Acta Chirurgica Latviensis ◽

10.2478/chilat-2013-0012 ◽

2013 ◽

Vol 13 (1) ◽

pp. 63-70

Author(s):

Ieva Vaivode ◽

Vilnis Lietuvietis ◽

Alinta Hegmane ◽

Iveta Kudaba

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Predictive Accuracy ◽

Treatment Strategies ◽

Simple Algorithm ◽

Mortality Data ◽

Routine Practice ◽

Clinical Scenarios ◽

Incidence And Mortality

Summary Morbidity and mortality data of RCC (renal cell carcinoma) differs a lot among the European countries. In Latvia a growing trend in both incidence and mortality rates is still observed. The expanding availability of multiple treatment strategies has increased the importance of skilled individualized outcome prediction for patients. Several prognostic factors are available in RCC including anatomical, histological, clinical and molecular ones, but none of them is very precise, when used alone. Therefore increasing number of prognostic systems has been created in local and metastatic disease to increase predictive accuracy. In order to encourage the clinicians to use the available models in their routine practice, we tried to select the most relevant ones and include them in a simple algorithm to be used in common clinical scenarios throughout entire history of the disease in patients with RCC

Download Full-text

Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now?

Journal of Kidney Cancer and VHL ◽

10.15586/jkcvhl.2014.19 ◽

2014 ◽

Vol 1 (8) ◽

pp. 84-98 ◽

Cited By ~ 7

Author(s):

Ana L Teixeira ◽

Francisca Dias ◽

Mónica Gomes ◽

Mara Fernandes ◽

Rui Medeiros

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Genetic Material ◽

Tumor Development ◽

Cell Communication ◽

Bioactive Molecules ◽

Screening Tests ◽

Transcriptional Level ◽

Incidence And Mortality

Renal cell carcinoma (RCC) is a lethal urological cancer, with incidence and mortality rates increasing by 2-3% per decade. The lack of standard screening tests contributes to the fact that one-third of patients are diagnosed with locally invasive or metastatic disease. Moreover, 20-40% of RCC patients submitted to surgical nephrectomy will develop metastasis. MicroRNAs (miRNAs) are small non-coding RNAs responsible for gene regulation at a post-transcriptional level. It is accepted that they are deregulated in cancer and can influence tumor development. Thus, miRNAs are promising RCC biomarkers, since they can be detected using non-invasive methods. They are highly stable and easier to quantify in circulating biofluids. The elevated miRNA stability in circulating samples may be the consequence of their capacity to circulate inside of extracellular microvesicles (EMVs), for example, the exosomes. The EMVs are bilayered membrane vesicles secreted by all cell types. They can be released in the interstitial space or into circulating biofluids, which allows the travelling, binding and entrance of these vesicles in receptor cells. This type of cell communication can shuttle bioactive molecules between cells, allowing the horizontal transference of genetic material. In this review, we focus on circulating miRNAs (miR-210, miR-1233, miR-221, miR-15a, miR-451, miR-508, miR-378) in the biofluids of RCC patients and attempt to establish the diagnostic and prognostic accuracy, their synergic effects, and the pathways involved in RCC biology.

Download Full-text

International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality

European Urology ◽

10.1016/j.eururo.2014.10.002 ◽

2015 ◽

Vol 67 (3) ◽

pp. 519-530 ◽

Cited By ~ 356

Author(s):

Ariana Znaor ◽

Joannie Lortet-Tieulent ◽

Mathieu Laversanne ◽

Ahmedin Jemal ◽

Freddie Bray

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Incidence And Mortality

Download Full-text

Apolipoprotein C1 stimulates the malignant process of renal cell carcinoma via the Wnt3a signaling

10.21203/rs.3.rs-29010/v3 ◽

2020 ◽

Author(s):

hao jiang ◽

Jing-Yuan Tang ◽

Dong Xue ◽

Yi-Meng Chen ◽

Ting-Chun Wu ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Nude Mice ◽

Renal Cell ◽

Prognostic Value ◽

Xenograft Model ◽

Underlying Mechanism ◽

Clinical Samples ◽

Incidence And Mortality

Abstract Background Renal cell carcinoma (RCC) is a clinically common tumor in the urinary system, showing an upward trend of both incidence and mortality. Apolipoprotein C1 (APOC1) has been identified as a vital regulator in tumor progression. This study aims to uncover the biological function of APOC1 in RCC process and the underlying mechanism. MethodsDifferential levels of APOC1 in RCC samples and normal tissues in a downloaded TCGA profile and clinical samples collected in our center were detected by quantitative reverse transcription PCR (qRT-PCR). The prognostic value of APOC1 in RCC was assessed by depicting Kaplan-Meier survival curves. After intervening APOC1 level by transfection of sh-APOC1 or oe-APOC1, changes in phenotypes of RCC cells were examined through CCK-8, colony formation, Transwell assay and flow cytometry. Subsequently, protein levels of EMT-related genes influenced by APOC1 were determined by Western blot. The involvement of the Wnt3a signaling in APOC1-regulated malignant process of RCC was then examined through a series of rescue experiments. Finally, a RCC xenograft model was generated in nude mice , aiming to further clarify the in vivo function of APOC1 in RCC process.ResultsAPOC1 was upregulated in RCC samples. Notably, its level was correlated to overall survival of RCC patients, displaying a certain prognostic value. APOC1 was able to stimulate proliferative, migratory and invasive abilities in RCC cells. The Wnt3a signaling was identified to be involved in APOC1-mediated RCC process. Notably, Wnt3a was able to reverse the regulatory effects of APOC1 on RCC cell phenotypes. In vivo knockdown of APOC1 in xenografted nude mice slowed down the growth of RCC.ConclusionsAPOC1 stimulates the malignant process of RCC via targeting the Wnt3a signaling.

Download Full-text